Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

15.17USD
16 Feb 2018
Change (% chg)

$-0.66 (-4.17%)
Prev Close
$15.83
Open
$15.48
Day's High
$15.83
Day's Low
$14.76
Volume
3,530,253
Avg. Vol
715,986
52-wk High
$17.40
52-wk Low
$5.87

Latest Key Developments (Source: Significant Developments)

Amicus Therapeutics Prices Underwritten Offering Of Common Stock
Thursday, 15 Feb 2018 07:00pm EST 

Feb 15 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK.SAYS OFFERING OF 19.4 MILLION COMMON SHARES PRICED AT $15.50PER SHARE.  Full Article

Amicus Therapeutics Announces Public Offering Of Common Stock
Wednesday, 14 Feb 2018 04:01pm EST 

Feb 14 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.AMICUS THERAPEUTICS INC - COMMENCED A $250 MILLION UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.AMICUS THERAPEUTICS INC - EXPECTS TO USE NET PROCEEDS OF OFFERING FOR INVESTMENT IN U.S., INTERNATIONAL COMMERCIAL INFRASTRUCTURE FOR MIGALASTAT HCL.AMICUS THERAPEUTICS INC - TO ALSO USE NET PROCEEDS OF OFFERING FOR INVESTMENT IN MANUFACTURING CAPABILITIES FOR ATB200, AMONG OTHERS.  Full Article

U.S. FDA Files NDA Under Priority Review For Migalastat
Monday, 12 Feb 2018 07:30am EST 

Feb 12 (Reuters) - Amicus Therapeutics Inc ::U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT GOAL DATE FOR FDA DECISION IS AUGUST 13, 2018.  Full Article

Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE.AMICUS THERAPEUTICS SEES GALAFOLD FY 2018 REVENUE $75 MILLION TO $85 MILLION.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED ABOUT $359 MILLION AT DEC 31, 2017.EXPECTS FULL-YEAR 2018 NET CASH SPEND OF BETWEEN $230 MILLION AND $260 MILLION.CURRENT CASH POSITION IS ANTICIPATED TO FUND ONGOING OPERATIONS INTO AT LEAST SECOND HALF OF 2019.FY2018 REVENUE VIEW $88.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat
Thursday, 14 Dec 2017 07:30am EST 

Dec 14 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - ‍LOOK FORWARD TO POTENTIAL U.S. APPROVAL OF MIGALASTAT IN 2018​.  Full Article

Amicus Therapeutics Q3 loss per share $0.69
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Amicus Therapeutics Inc ::Amicus therapeutics announces third quarter 2017 financial results and corporate updates.Q3 loss per share $0.69.Q3 revenue $10.9 million versus I/B/E/S view $9.5 million.Q3 adjusted loss per share $0.41 excluding items.Q3 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.Amicus Therapeutics Inc - ‍reiterated full-year 2017 financial guidance​.Amicus Therapeutics Inc - ‍current cash position anticipated to fund ongoing operations into at least H2 2019​.  Full Article

Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society
Wednesday, 4 Oct 2017 06:00am EDT 

Oct 4 (Reuters) - Amicus Therapeutics Inc : :Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society.Amicus Therapeutics Inc - ‍pulmonary function generally improved or remained stable at 6 and 9 months​.Amicus Therapeutics - plans to continue collaborative discussions with regulators in US and EU, expects to provide update in first half of 2018.  Full Article

Amicus Therapeutics says U.S. FDA granted orphan drug designation to ATB200/AT2221 for Pompe disease
Thursday, 21 Sep 2017 07:30am EDT 

Sept 21 (Reuters) - Amicus Therapeutics Inc :Says ‍U.S. FDA has granted orphan drug designation to ATB200/AT2221​ for Pompe disease​.Amicus Therapeutics - ‍look forward to announcing new clinical data in all patients from ATB200/AT2221​ study at World Muscle Society in early Oct.  Full Article

U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease
Tuesday, 19 Sep 2017 07:30am EDT 

Sept 19 (Reuters) - Amicus Therapeutics Inc :U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease.Amicus Therapeutics Inc - ‍company plans to submit a new drug application (NDA) for migalastat in Q4 of 2017​.  Full Article

Amicus Therapeutics announces approval for Galafold™ for treatment of Fabry disease in Canada
Thursday, 14 Sep 2017 04:01pm EDT 

Sept 15 (Reuters) - Amicus Therapeutics Inc :Amicus Therapeutics Inc announces approval for Galafold™ (Migalastat) for treatment of Fabry disease in Canada.Amicus Therapeutics Inc - ‍Amicus expects to make Galafold available to Canadian patients in coming weeks​.Amicus Therapeutics Inc says ‍following Health Canada approval, Amicus expects to make Galafold available to Canadian patients in coming weeks.​.  Full Article